Current therapeutic recommendations: Infliximab for ulcerative colitis

Journal of Clinical Gastroenterology

Volumn 38, Issue 9, 2004, Pages 741-745

  Shen, Eric Hung ^a   Das, Kiron Moy ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Infliximab; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; CORTICOSTEROID; CYTOKINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; COLITIS; COLON BIOPSY; COLON RESECTION; CONTROLLED STUDY; DRUG MECHANISM; ENTERITIS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MAJOR CLINICAL STUDY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; HUMANS; PRACTICE GUIDELINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4644336752     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000140188.88275.65     Document Type: Review

References (41)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med. 1997;337:1029-1035.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
3. Colombes JF, Loftus E, Tremaine W. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic Experience on 500 patients. Gastroenterology. 2004;126:19-31.
4. Das KM, Eastwood MA, McManus J, et al. The metabolism of salicylazo-sulfapyridine in ulcerative colitis. Gut. 1973;14:631-641.
5. Das KM. Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol Clin N Am. 1989;18:1-20.
6. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol. 1993;88:1188-1197.
7. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulfasalazine (salazopyrine). Gut. 1973;14:923-926.
8. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993;118:540-549.
9. Prakash A, Markham A. Oral delayed-release mesalazine: A review of its use in ulcerative colitis and Crohn's disease. Drugs. 1999;57:383-408.
10. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975;69:96.
11. Glazier KD, Palance A, Griffel LH, et al. The 10-year experience with purinethol(6MP) at the Crohn's and Colitis Center of NJ. Gastroenterology. 2001;120:A76.
12. Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740-746.
13. Hearing SD, Norman M, Probert CSJ, et al. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocyte. Gut. 1999;45:382-388.
14. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-1845.
15. Gurudu SR, Griffel LH, Gianella RJ, et al. Cyclosporine therapy in inflammatory bowel disease, short term and long term results. J Clin Gastroenterol. 1999;29:151-154.
16. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94:1587-1592.
17. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
18. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
19. Geng X, Biancone L, Dai H, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to Tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912-922.
20. Sakamaki S, Takayanagi N, Yoshizaki N, et al. Autoantibodies against the specific epitope of human tropomyosin(s) detected by patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPW9 transfected L cells. Gut. 2000;47:236-241.
21. Inoue N, Watnabe M, Sato T, et al. Restricted VH gene usage in lamina propria B cells producing anticolon antibody from patients with ulcerative colitis. Gastroenterology. 2001;121:15-23.
22. Taniguchi M, Geng X, Glazier K, et al. Cellular immune response against Tropomyosin Isoform 5 in ulcerative colitis. Clin Immunol. 2001;101:289-295.
23. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol. 1999;94:2923-2928.
24. Guimbaud R, Bertrand V, Chauvelot-Moachon L, et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol. 1998;93:2397-2404.
25. Tsukada Y, Nakamura T, Imura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytopheresis. Am J Gastroenterol. 2002;97:2820-2828.
26. Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut. 1995;37:260-263.
27. Watkins PE, Foulkes R, Ward P, et al. Faecal tumour necrosis factor alpha in cottontop tamarin colitis. [Abstract] J Pathol. 1993;70:364A.
28. Evans RC, Clarke L, Heath P, et al. Treatment of ulcerative colitis with an engineered anti-TNF[alpha]-alpha antibody CDP 571. Aliment Pharmacol Ther. 1997;11:1031-1035.
29. Scallon BJ, Moore MA, Trinth H, et al. Chimeric anti-TNF-alpha monoclonal-antibody CA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259.
30. Schmidt M, Luegering N, Luegering A, et al. Infliximab exerts anti-inflammatory capacity in IBD by induction of apoptosis in monocytes. Gastroenterology. 2000;118(suppl 2):3630.
31. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
32. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2373-2381.
33. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2001;7(suppl 1):s30-s33.
34. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88.
35. Kaser A, Marringer T, Voel T, et al. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2001;113:930-933.
36. Mamula P, Markowitz J, Jonathan E, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002;34:307-311.
37. Kohn A, Prantera C, Pera A, et al. Anti-tumour necrosis factor (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis. 2002;34:626-630.
38. Actis GC, Bruno M, Pinna-Pintor M, et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis. 2002;34:631-634.
39. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:2577-2584.
40. Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut. 2003;52:998-1002.
41. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003;18:175-181.